Of all the regulatory tools available to the FDA in fulfilling its duties, one of the most contentious and problematic is its use of adverse publicity. Whether it is because of its quasi-statutory status, the questionable legality of its often unregulated use, or its great potential for harm to those it is directed at, there are many who object to the use of adverse publicity by the FDA. However, one cannot deny its significant effectiveness as a regulatory tool and its often necessary and justified use in protecting the public health and safety. The purpose of this paper, then, is to explore the FDA's use of adverse publicity and the issues and conflicts that arise as a result
The Federal Food, Drug, and Cosmetic Act (FDCA) does not expressly prohibit companies from marketing...
Section 704 of the Federal Food, Drug and Cosmetic Act authorizes the Food and Drug Administration t...
There have been considerable charges and counter-charges the United States Food and Drug Administra...
This paper seeks (1) to provide the background necessary to understand current commercial speech jur...
In 1938 the Food and Drug Administration (FDA) adopted regulations which created a category of presc...
This paper is a study of how the American people interact with and understand a complicated governme...
Last year alone, doctors filled out over four billion drug prescriptions in the United States. But a...
This paper discusses the history of the FDA with a focus on the expansion of FDA regulatory powers
Off-label drug or medical device “use” is the practice of prescribing drugs or medical devices to pa...
OBJEcnVE: To reviewsome of the abusesand proper uses of the Foodand Drug Administration's (FDA&...
In evaluating the United States drug regulatory system in 1978, Richard J. Crout posed a choice betw...
Pharmaceutical companies face increasing pressure to bring new treatments to market in order to surv...
This article discusses how the Food and Drug Administration has come to adopt informal guidance (age...
This paper analyzes the relationship between postmarketing promotional activity and reporting of adv...
The Food and Drug Administration (FDA) has developed an informal framework for regulating press rele...
The Federal Food, Drug, and Cosmetic Act (FDCA) does not expressly prohibit companies from marketing...
Section 704 of the Federal Food, Drug and Cosmetic Act authorizes the Food and Drug Administration t...
There have been considerable charges and counter-charges the United States Food and Drug Administra...
This paper seeks (1) to provide the background necessary to understand current commercial speech jur...
In 1938 the Food and Drug Administration (FDA) adopted regulations which created a category of presc...
This paper is a study of how the American people interact with and understand a complicated governme...
Last year alone, doctors filled out over four billion drug prescriptions in the United States. But a...
This paper discusses the history of the FDA with a focus on the expansion of FDA regulatory powers
Off-label drug or medical device “use” is the practice of prescribing drugs or medical devices to pa...
OBJEcnVE: To reviewsome of the abusesand proper uses of the Foodand Drug Administration's (FDA&...
In evaluating the United States drug regulatory system in 1978, Richard J. Crout posed a choice betw...
Pharmaceutical companies face increasing pressure to bring new treatments to market in order to surv...
This article discusses how the Food and Drug Administration has come to adopt informal guidance (age...
This paper analyzes the relationship between postmarketing promotional activity and reporting of adv...
The Food and Drug Administration (FDA) has developed an informal framework for regulating press rele...
The Federal Food, Drug, and Cosmetic Act (FDCA) does not expressly prohibit companies from marketing...
Section 704 of the Federal Food, Drug and Cosmetic Act authorizes the Food and Drug Administration t...
There have been considerable charges and counter-charges the United States Food and Drug Administra...